There are lots of different tools investors use to build […]
Novo Nordisk's shares plummeted on Tuesday, falling as much as 14% after the company announced a decline in sales and profit growth for 2026.
The company pointed to lower prices in the U.S. and the loss of exclusivity for its popular drugs, Wegovy and Ozempic, in several international markets, including China, Brazil, and Canada.
For the upcoming year, Novo Nordisk expects sales and operating profits to decline between 5% and 13% at constant exchange rates.
This forecast is significantly worse than what analysts had anticipated. The company is currently facing challenges in its largest market, the U.S., which is impacting its overall performance.
Despite the ominous outlook for 2026, Novo Nordisk reported a 10% increase in sales and a 6% increase in operating profit for 2025.
In the fourth quarter, the company saw net sales total 79.1 billion Danish kroner, which is equivalent to about $12.5 billion, slightly exceeding the analysts' expectations of 77.8 billion kroner.
In the fourth quarter, Novo Nordisk's best-selling drug, Ozempic, generated sales of 31.8 billion kroner, marking a 1% increase compared to the same period last year.
Additionally, Wegovy sales reached 21.9 billion kroner, reflecting a 17% increase year-over-year.
With increasing competition from Eli Lilly's weight-loss drug, tirzepatide, Novo Nordisk is striving to regain market share in the U.S. market.
The company is optimistic about launching Wegovy in more countries in 2026 and introducing a higher 7.2 mg dose in several markets.
Moving forward, Novo Nordisk is focusing on the U.S. launch of the oral version of Wegovy. CEO Mike Doustdar expressed confidence in the drug's potential to drive volume growth in the coming years, despite the current pricing pressures and competition.
Investors remain cautious, however, as they await updates on Novo’s strategy to navigate the shifting market dynamics.
There are lots of different tools investors use to build […]
When most people think about Wall Street, they imagine billions […]
The space race originally started to send astronauts to the […]
Every investor knows: The goal of investing is to watch […]
Every quarter and year, companies report their earnings. These reports […]
What Are Precious Metals (And Why Should You Care)? When […]
Japan's Wall Street Is Changing Fast The Kabutocho district has […]
Why USAR Stock Is Getting Attention In 2026 In case […]
What Is the Price-to-Sales Ratio? Here's the deal: Not every […]
Annuities are one of the most misunderstood financial products out […]
